Intrepid Financial Planning Group LLC Has $125,000 Stock Holdings in Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS)

by · The Cerbat Gem

Intrepid Financial Planning Group LLC lifted its stake in Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS – Free Report) by 49.6% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 30,150 shares of the company’s stock after acquiring an additional 10,000 shares during the quarter. Intrepid Financial Planning Group LLC owned approximately 0.05% of Acumen Pharmaceuticals worth $125,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also modified their holdings of the stock. UBS Group AG bought a new stake in Acumen Pharmaceuticals in the third quarter worth $27,000. California State Teachers Retirement System boosted its holdings in Acumen Pharmaceuticals by 114.9% in the first quarter. California State Teachers Retirement System now owns 12,162 shares of the company’s stock worth $48,000 after purchasing an additional 6,503 shares in the last quarter. Jane Street Group LLC bought a new stake in Acumen Pharmaceuticals in the fourth quarter worth $55,000. American International Group Inc. boosted its holdings in Acumen Pharmaceuticals by 163.3% during the first quarter. American International Group Inc. now owns 14,047 shares of the company’s stock valued at $55,000 after acquiring an additional 8,712 shares during the period. Finally, Chicago Partners Investment Group LLC bought a new stake in Acumen Pharmaceuticals during the third quarter valued at about $56,000. 51.62% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Acumen Pharmaceuticals

In other news, CEO Daniel Joseph Oconnell sold 15,200 shares of the stock in a transaction that occurred on Friday, January 19th. The shares were sold at an average price of $3.47, for a total transaction of $52,744.00. Following the sale, the chief executive officer now directly owns 502,485 shares of the company’s stock, valued at $1,743,622.95. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, CEO Daniel Joseph Oconnell sold 15,200 shares of the stock in a transaction that occurred on Friday, January 19th. The shares were sold at an average price of $3.47, for a total transaction of $52,744.00. Following the sale, the chief executive officer now directly owns 502,485 shares of the company’s stock, valued at $1,743,622.95. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Derek M. Meisner sold 8,933 shares of the stock in a transaction that occurred on Friday, January 19th. The shares were sold at an average price of $3.48, for a total transaction of $31,086.84. Following the sale, the insider now directly owns 108,867 shares in the company, valued at $378,857.16. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 31,208 shares of company stock valued at $110,136. Corporate insiders own 7.50% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Deutsche Bank Aktiengesellschaft initiated coverage on shares of Acumen Pharmaceuticals in a research report on Tuesday, December 12th. They set a “buy” rating and a $8.00 price objective for the company. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock has an average rating of “Buy” and an average price target of $12.25.

Get Our Latest Stock Analysis on Acumen Pharmaceuticals

Acumen Pharmaceuticals Trading Down 5.5 %

NASDAQ:ABOS traded down $0.20 during mid-day trading on Monday, hitting $3.42. The company’s stock had a trading volume of 282,497 shares, compared to its average volume of 521,086. Acumen Pharmaceuticals, Inc. has a fifty-two week low of $1.81 and a fifty-two week high of $11.31. The company has a market capitalization of $198.05 million, a price-to-earnings ratio of -3.06 and a beta of -0.08. The stock has a fifty day moving average of $3.13 and a 200-day moving average of $4.49.

Acumen Pharmaceuticals (NASDAQ:ABOS – Get Free Report) last posted its quarterly earnings results on Monday, November 13th. The company reported ($0.24) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.31) by $0.07. During the same quarter last year, the business posted ($0.26) earnings per share. On average, equities analysts anticipate that Acumen Pharmaceuticals, Inc. will post -1.11 earnings per share for the current fiscal year.

Acumen Pharmaceuticals Company Profile

(Free Report)

Acumen Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers.

Featured Articles